ALXO CEO receives 597,500 stock options; vesting in 2026

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. (ALXO) reported an insider equity grant. The company’s Chief Executive Officer and Director received an employee stock option for 597,500 shares at an exercise price of $1.70 on October 14, 2025, expiring on October 14, 2035.

Vesting is staged: one‑third vests on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the grant, 597,500 derivative securities were beneficially owned, held directly.

Insights

Equity compensation analyst

Routine CEO option grant with defined vesting milestones.

The filing shows an employee stock option grant covering 597,500 shares with a strike price of $1.70. The option was granted on October 14, 2025 and expires on October 14, 2035, which is a standard 10‑year term for such awards.

Vesting is time‑based: one‑third on April 30, 2026 and the remaining two‑thirds on October 31, 2026. The award is listed as directly owned, and the grant price of the derivative is $0, consistent with a compensatory option grant.

The entry is administrative in nature; actual impact depends on future service through the vesting dates and market price relative to the $1.70 exercise price.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lettmann Jason

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.7	10/14/2025		A		597,500		(1)	10/14/2035	Common Stock	597,500	$0	597,500	D

Explanation of Responses:

1. One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.

	/s/ Shelly Pinto, by power of attorney	10/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ALXO disclose in this Form 4?

An employee stock option grant to the CEO/Director for 597,500 shares at an exercise price of $1.70.

When was the option granted and when does it expire for ALXO?

The option was granted on October 14, 2025 and expires on October 14, 2035.

What is the vesting schedule for the ALXO CEO’s option?

One‑third vests on April 30, 2026; the remaining two‑thirds vests on October 31, 2026.

How many derivative securities did the insider hold after the transaction?

The insider beneficially owned 597,500 derivative securities following the grant.

What is the ownership form of the ALXO option grant?

The filing reports direct ownership of the derivative securities.

Who is the reporting person’s relationship to ALXO?

The reporting person is both a Director and the Chief Executive Officer.